BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Department of Medicine - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.med.unc.edu/medicine
X-WR-CALDESC:Events for Department of Medicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180531T120000
DTEND;TZID=America/New_York:20180531T130000
DTSTAMP:20260617T201223
CREATED:20180531T160000Z
LAST-MODIFIED:20190307T184241Z
UID:10000997-1527768000-1527771600@www.med.unc.edu
SUMMARY:Medicine Grand Rounds\, Saira Sheikh “BAFFling New Lupus Therapies – Looking to the Future After Decades of Failed Clinical Trials”
DESCRIPTION:Systemic lupus erythematosus (SLE) is a chronic\, debilitating autoimmune disease with heterogeneous manifestations ranging from scarring skin rash or arthritis to severe\, organ-threatening involvement of the kidneys\, heart\, lungs or central nervous system. SLE is characterized by the presence of autoantibodies against nuclear antigens\, which are thought to be caused by dysregulation of the immune system. Development of new therapies is critical due to unmet needs associated with SLE\, including inadequate disease control\, poor health-related quality of life\, medication toxicities and increased morbidity and mortality. \nOne challenge in caring for patients with SLE is a lack of approved and efficacious medications. Randomized controlled trials evaluating novel biologic immune modulators in SLE have been largely unsuccessful at achieving the primary endpoints needed for FDA approval. Efforts to develop therapies against specific molecular targets in SLE has resulted in the identification of BAFF (B-cell activating factor) inhibitors to treat the disease. This talk will provide a summary of that journey and a brief overview of what’s on the horizon for SLE therapies. \nDr. Saira Sheikh is an Assistant Professor of Medicine\, Director of Clinical Trials Program at the UNC Thurston Arthritis Research Center and Director of the UNC Rheumatology Lupus Clinic. Dr. Sheikh’s work has been focused on building a Collaborative Lupus Clinical & Research Program that directly impacts the care of patients. She is working on a national level to develop programs that address racial disparities in lupus clinical trials.
URL:https://www.med.unc.edu/medicine/event/may-31/
CATEGORIES:Medicine Grand Rounds
ATTACH;FMTTYPE=image/png:https://www.med.unc.edu/medicine/wp-content/uploads/sites/945/2018/12/saira-sheikh.png
END:VEVENT
END:VCALENDAR